Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
GILD filed a Form 144 reporting proposed sales of specified common stock. The notice lists a Stock Option Exercise of 25,000 shares dated 05/15/2026, 494 restricted shares dated 12/10/2024, and 2,506 performance shares dated 02/04/2025.
The filing also records sales by Johanna Mercier in the prior three months: 3,000 shares on 04/15/2026 ($422,880.00), 3,000 shares on 03/16/2026 ($432,690.00), and 28,000 shares on 02/17/2026 ($4,324,227.70).
Andrew Dickinson submitted a Form 144 notice indicating a proposed sale of 3,000 shares of Common Stock described as Performance Shares (issued 01/24/2023) through Morgan Stanley Smith Barney LLC. The filing also lists three recent sales of 3,000 shares each on 02/17/2026, 03/16/2026, and 04/15/2026 with reported proceeds.
Gilead Sciences, Inc. is offering multiple series of senior unsecured notes under a preliminary prospectus supplement related to an effective shelf registration. The notes will be senior unsecured obligations that rank equally with Gilead’s other senior unsecured debt, will be issued in book-entry form through DTC and are payable semiannually commencing in 2026.
The indenture permits optional redemption (including at Par Call Dates) and requires an offer to repurchase the notes at 101% of principal upon a Change of Control Triggering Event. Net proceeds are designated for general corporate purposes. The prospectus supplement incorporates certain SEC filings by reference, including the Form 10-K for the year ended and Form 10-Q for the quarter ended .
GILEAD SCIENCES, INC. filed a Form 13F reporting its institutional investment manager holdings. The report lists 6 information-table entries with a total reported market value of $2,117,784,504. The filing names Gilead Therapeutics A1 Unlimited Co as an other included manager and is signed by CFO Andrew D. Dickinson on 05-08-2026.
Gilead Sciences reported higher profit and revenue for the quarter ended March 31, 2026. Total revenues rose to $6.96 billion from $6.67 billion, driven mainly by 10% growth in HIV product sales to $5.03 billion and 37% growth in Trodelvy oncology sales to $402 million, partly offset by a 52% decline in Veklury COVID-19 sales to $144 million and lower cell therapy revenue.
Net income increased to $2.02 billion from $1.32 billion, and diluted earnings per share rose to $1.61 from $1.04, helped by higher product sales, lower acquired in‑process R&D expenses and net unrealized gains on equity securities. Operating cash flow strengthened to $2.54 billion, and the company ended the quarter with $7.63 billion in cash and cash equivalents.
Looking ahead, Gilead expects a large non‑recurring charge. Management plans to record about $11.5 billion of acquired in‑process R&D expense in the second quarter of 2026 tied to recent Arcellx, Tubulis and Ouro transactions, and indicates this will result in a net loss for both the second quarter and full year 2026 despite solid underlying operations.
Gilead Sciences reported first quarter 2026 revenue of $6.96 billion, up 4% year over year, driven by 10% HIV growth to $5.03 billion and strong contributions from Trodelvy and Livdelzi, partly offset by a 52% decline in Veklury to $144 million and softer Cell Therapy sales.
GAAP diluted EPS rose to $1.61 from $1.04, and non-GAAP diluted EPS increased to $2.03 from $1.81, helped by higher product sales, net unrealized gains on equity securities, and lower acquired IPR&D expenses.
For full year 2026, Gilead raised product sales guidance to $30.0–$30.4 billion and product sales excluding Veklury to $29.4–$29.8 billion, but now expects a GAAP diluted loss per share of $(3.25) to $(2.85) and a non-GAAP diluted loss per share of $(1.05) to $(0.65), primarily due to $11.5 billion anticipated acquired IPR&D charges and financing costs tied to the Arcellx, Ouro and Tubulis transactions.
Gilead Sciences director Jeffrey Bluestone reported new equity awards. He received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, each representing one share of common stock, and the RSUs vested immediately on April 30, 2026. He was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with 100% of the option vesting immediately on the same date. Following these transactions, he holds 10,066 shares of Gilead common stock directly, in addition to the option position.
Gilead Sciences director Jacqueline K. Barton received equity compensation on April 30, 2026. She was granted 1,146 restricted stock units that vested immediately, each representing one share of common stock, bringing her direct holdings to 27,202 shares. She also received a non-qualified stock option for 4,884 shares at an exercise price of $130.84 per share, with all option shares vesting immediately and expiring on April 30, 2036.
Gilead Sciences director Sandra Horning reported new equity compensation awards. She received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, with each RSU representing one share of common stock and vesting immediately on April 30, 2026.
She was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, which vested 100% on April 30, 2026 and expires on April 30, 2036. Following these awards, she directly holds 6,293 shares of Gilead common stock.
Gilead Sciences director Ted W. Love received new equity awards as part of his compensation. On April 30, 2026, he was granted 1,146 restricted stock units under the 2022 Equity Incentive Plan. Each RSU represents one share of common stock and vested immediately on the grant date.
On the same date, he was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with all shares under the option vesting immediately and expiring on April 30, 2036. Following these awards, he directly holds 5,484 common shares and 4,884 options.